Inventor · disambiguated record
Li Tan
Also filed as: TAN LI · TAN LI K · TAN LI KIANG · TAN LI XUAN
13 granted patents·8 pending applications·92 citations·filing 2001–2023
90Inventor score
Top patents by PatentIndex Score
21 records- 0194US10017477B2Janus kinase inhibitors and uses thereofDANA FARBER CANCER INST INC·Filed 2015·Granted Jul 10, 2018·20 cites·27 claims
- 0294US9862688B2Hydrophobically tagged janus kinase inhibitors and uses thereofDANA FARBER CANCER INST INC·Filed 2015·Granted Jan 9, 2018·22 cites·40 claims
- 0392US9783504B2Kinase inhibitors for the treatment of diseaseDANA FARBER CANCER INST INC·Filed 2014·Granted Oct 10, 2017·21 cites·27 claims
- 0490US10316002B2Kinase inhibitors for the treatment of diseaseDANA FARBER CANCER INST INC·Filed 2017·Granted Jun 11, 2019·9 cites·18 claims
- 0589US9856223B2Methods to treat lymphoplasmacytic lymphomaDANA FARBER CANCER INST INC·Filed 2014·Granted Jan 2, 2018·6 cites·23 claims
- 0684US10525060B2HCK as a therapeutic target in MYD88 mutated diseasesDANA FARBER CANCER INST INC·Filed 2017·Granted Jan 7, 2020·5 cites·15 claims
- 0783US9908872B2Methods to treat lymphoplasmacytic lymphomaDANA FARBER CANCER INST INC·Filed 2014·Granted Mar 6, 2018·6 cites·26 claims
- 0881US10633348B2Methods to treat lymphoplasmacytic lymphomaDANA FARBER CANCER INST INC·Filed 2017·Granted Apr 28, 2020·1 cites·29 claims
- 0973US10597387B2Methods to treat lymphoplasmacytic lymphomaDANA FARBER CANCER INST INC·Filed 2018·Granted Mar 24, 2020·1 cites·30 claims
- 1065USRE50030EMethods to treat lymphoplasmacytic lymphomaDANA FARBER CANCER INST INC·Filed 2014·Granted Jul 2, 2024·0 cites·33 claims
- 1165US10906878B2Kinase inhibitors for the treatment of diseaseDANA FARBER CANCER INST INC·Filed 2019·Granted Feb 2, 2021·0 cites·20 claims
- 1262US10124008B2Use of inhibitors of acid sphingomyelinase to treat acquired and inherited retinal degenerationsWISCONSIN ALUMNI RES FOUND·Filed 2015·Granted Nov 13, 2018·1 cites·10 claims
- 1356US2025295678A1Ultra low dosage zoledronic acid for treatment of retinal diseaseUNIV CALIFORNIA·Filed 2023·Application pending·0 cites
- 1455US10925868B2Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of useDANA FARBER CANCER INST INC·Filed 2017·Granted Feb 23, 2021·0 cites·19 claims
- 1555US2024209038A1Targeting piezo1 to treat inherited and age-related macular degenerationsUNIV CALIFORNIA·Filed 2022·Application pending·0 cites
- 1653US2024034726A9Map kinase kinase (mkk7) inhibitors and uses thereofDANA FARBER CANCER INST INC·Filed 2021·Application pending·0 cites
- 1753US2023339865A1Quinazoline-derived hck inhibitors for use in the treatment of myd88 mutated diseasesDANA FARBER CANCER INST INC·Filed 2021·Application pending·0 cites
- 1851US2023058545A1Hck as a therapeutic target in myd88 mutated diseasesDANA FARBER CANCER INST INC·Filed 2020·Application pending·0 cites
- 1951US2022372017A1Hck degraders and uses thereofDANA FARBER CANCER INST INC·Filed 2020·Application pending·0 cites
- 2046US2006234290A1Novel genes and expression products therefromCHUNG CHING M·Filed 2006·Application pending·0 cites
- 2140US2002107190A1Novel genes and expression products therefromFiled 2001·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Li Tan files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →